ValuEngine upgraded shares of DexCom, Inc. (NASDAQ:DXCM) from a sell rating to a hold rating in a report published on Monday, November 6th.
Several other equities research analysts also recently commented on the stock. Morgan Stanley lowered their target price on shares of DexCom from $72.00 to $52.00 and set a neutral rating for the company in a research note on Friday, November 3rd. Barclays PLC reduced their price target on shares of DexCom from $60.00 to $57.00 and set an equal weight rating for the company in a report on Thursday, November 2nd. Northland Securities restated a hold rating and set a $50.00 target price on shares of DexCom in a report on Thursday, November 2nd. TheStreet cut shares of DexCom from a c- rating to a d+ rating in a report on Wednesday, October 25th. Finally, Zacks Investment Research cut shares of DexCom from a hold rating to a sell rating in a report on Tuesday, October 24th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and fourteen have issued a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average target price of $70.69.
Shares of DexCom (NASDAQ:DXCM) traded up $0.99 during trading hours on Monday, reaching $54.01. 1,530,519 shares of the company’s stock traded hands, compared to its average volume of 1,594,893. DexCom has a 1 year low of $42.62 and a 1 year high of $88.80. The company has a quick ratio of 5.50, a current ratio of 5.86 and a debt-to-equity ratio of 0.84.
In other news, Director Steven R. Altman purchased 10,000 shares of the stock in a transaction on Monday, November 6th. The stock was purchased at an average price of $49.61 per share, for a total transaction of $496,100.00. Following the acquisition, the director now owns 4,353 shares in the company, valued at $215,952.33. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Richard Doubleday sold 1,635 shares of the firm’s stock in a transaction that occurred on Monday, October 23rd. The stock was sold at an average price of $44.82, for a total transaction of $73,280.70. Following the transaction, the executive vice president now owns 65,049 shares of the company’s stock, valued at approximately $2,915,496.18. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 13,964 shares of company stock worth $948,039. 1.70% of the stock is owned by corporate insiders.
Several large investors have recently added to or reduced their stakes in the company. FMR LLC increased its stake in shares of DexCom by 9.9% in the 2nd quarter. FMR LLC now owns 10,824,306 shares of the medical device company’s stock valued at $791,799,000 after acquiring an additional 978,898 shares in the last quarter. Janus Henderson Group PLC grew its position in DexCom by 29.2% in the 3rd quarter. Janus Henderson Group PLC now owns 8,819,825 shares of the medical device company’s stock valued at $431,510,000 after purchasing an additional 1,991,094 shares during the period. Vanguard Group Inc. grew its position in DexCom by 3.4% in the 2nd quarter. Vanguard Group Inc. now owns 6,821,102 shares of the medical device company’s stock valued at $498,963,000 after purchasing an additional 224,808 shares during the period. BlackRock Inc. grew its position in DexCom by 5.5% in the 2nd quarter. BlackRock Inc. now owns 4,391,404 shares of the medical device company’s stock valued at $321,232,000 after purchasing an additional 230,542 shares during the period. Finally, Brown Advisory Inc. grew its position in DexCom by 57.2% in the 3rd quarter. Brown Advisory Inc. now owns 4,165,522 shares of the medical device company’s stock valued at $203,798,000 after purchasing an additional 1,515,134 shares during the period.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with our FREE daily email newsletter.